Full Program Just Released!
Your Flagship Event Driving ADC Innovation, Insights & Connections

Pfizer pens $10B, 12-drug deal with Innovent in broad bet on Chinese cancer med innovation
Bristol Myers’ $800M bispecific ADC aces China breast cancer study, putting TROP2 drugs on notice
Regeneron pens $2.3B pact with Parabilis to develop new type of ADC-like therapy
Daiichi, AstraZeneca’s Enhertu breaks into early breast cancer with dual FDA approvals

Utilizing Bispecific ADCs to Expand a Narrow Range of Tumor Antigens Through Innovative Target Pairing

Utilizing Bispecific ADCs to Expand a Narrow Range of Tumor Antigens Through Innovative Target Pairing

By | 8 June 2026